Categories: BrainNews

Soterix Medical Announces FDA 510(k) Clearance of MEGA-IOM Intraoperative Neuromonitoring System

WOODBRIDGE, N.J., July 24, 2024 /PRNewswire/ — Soterix Medical Inc., the global leader in stimulation and synergistic monitoring technologies, announced today it has received a 510(k) clearance from the U.S. Food & Drug Administration for its Intraoperative Neurophysiologic Monitoring (IOM) system, MEGA-IOM. The system provides unmatched integrated control of central and peripheral nervous systems to reduce postoperative risk and improve surgical outcomes. ­It includes preset modalities such as motor evoked potentials (MEP) to evaluate the integrity of motor pathways, somatosensory evoked potentials (SSEP) to evaluate the integrity of sensory pathways and detect brain and spinal cord ischemia, EEG to record and analyze brain activity (functional state of the brain), and direct stimulation to control the functional integrity of peripheral nerves.

MEGA-IOM provides unmatched integrated control of central and peripheral nervous systems to reduce postoperative risk.

“This FDA authorization represents a significant milestone for our organization as we can now offer the MEGA-IOM system to surgical teams across the U.S.,” said Ms. Danielle Dadona, VP of Regulatory Affairs of Soterix Medical. “This U.S. manufactured system pairs with an intuitive, rich, software interface with exceptional usability.”

Mr. Kamran Nazim, Chief Product Officer of Soterix Medical commented “MEGA-IOM is a cutting-edge modular platform solution that combines years of knowledge and experience obtained in clinical and research environments. Due to flexible channel configuration and size options (cart-based or portable), the system can meet the most exacting needs of both surgeons and advanced neuromonitoring specialists.”

Surgeons, neurophysiologists, neurologists and intraoperative monitoring service companies in the United States interested in incorporating the MEGA-IOM system are eligible for Soterix Medical’s Partnership program which includes support on the entire system, hands-on training and staff certification. Interested parties should contact Soterix Medical (at contact@soterixmedical.com) for additional information.

Media Contact: Chaya Edelman
Tel: +1-888-990-8327
Email: contact@soterixmedical.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/soterix-medical-announces-fda-510k-clearance-of-mega-iom-intraoperative-neuromonitoring-system-302204284.html

SOURCE Soterix Medical, Inc.

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

23 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

23 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

23 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

23 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

23 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

23 hours ago